Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study

Objectives To test whether bisphosphonate use is related to improved implant survival after total arthroplasty of the knee or hip. Design Population based retrospective cohort study. Setting Primary care data from the United Kingdom. Participants All patients undergoing primary total arthroplasty of the knee (n=18 726) or hip (n=23 269) in 1986-2006 within the United Kingdom’s General Practice Research Database. We excluded patients with a history of hip fracture before surgery or rheumatoid arthritis, and individuals younger than 40 years at surgery. Intervention Bisphosphonate users were classified as patients with at least six prescriptions of bisphosphonates or at least six months of prescribed bisphosphonate treatment with more than 80% adherence before revision surgery. Outcome measures Revision arthroplasties occurring after surgery, identified by READ and OXMIS codes. Parametric survival models were used to determine effects on implant survival with propensity score adjustment to account for confounding by indication. ResultsOf 41 995 patients undergoing primary hip or knee arthroplasty, we identified 1912 bisphosphonate users, who had a lower rate of revision at five years than non-users (0.93% (95% confidence interval 0.52% to 1.68%) v 1.96% (1.80% to 2.14%)). Implant survival was significantly longer in bisphosphonate users than in non-users in propensity adjusted models (hazard ratio 0.54 (0.29 to 0.99); P=0.047) and had an almost twofold increase in time to revision after hip or knee arthroplasty (time ratio 1.96 (1.01 to 3.82)). Assuming 2% failure over five years, we estimated that the number to treat to avoid one revision was 107 for oral bisphosphonates. Conclusions In patients undergoing lower limb arthroplasty, bisphosphonate use was associated with an almost twofold increase in implant survival time. These findings require replication and testing in experimental studies for confirmation.

[1]  Shigui Yan,et al.  Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials , 2012, Osteoporosis International.

[2]  K. Michaëlsson,et al.  Bisphosphonate use and atypical fractures of the femoral shaft. , 2011, The New England journal of medicine.

[3]  C. Cooper,et al.  Bisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysis , 2011, Osteoporosis International.

[4]  Zong-ke Zhou,et al.  A systematic review assessing the effectiveness of alendronate in reducing periprosthetic bone loss after cementless primary THA. , 2011, Orthopedics.

[5]  G G Koch,et al.  One in four people may develop symptomatic hip osteoarthritis in his or her lifetime. , 2010, Osteoarthritis and cartilage.

[6]  C. Cooper,et al.  Changes in hip fracture rate before and after total knee replacement due to osteoarthritis: a population-based cohort study , 2010, Annals of the rheumatic diseases.

[7]  T. Thillemann,et al.  Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. , 2010, Bone.

[8]  R. D. de Steiger,et al.  Poor outcome of revised resurfacing hip arthroplasty , 2010, Acta orthopaedica.

[9]  F. Hossain,et al.  Midterm Assessment of Causes and Results of Revision Total Knee Arthroplasty , 2010, Clinical orthopaedics and related research.

[10]  Emma Smith,et al.  Recurrent and injurious falls in the year following hip fracture: a prospective study of incidence and risk factors from the Sarcopenia and Hip Fracture study. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.

[11]  P. Rehak,et al.  The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. , 2009, The Journal of bone and joint surgery. American volume.

[12]  R. Tannen,et al.  Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings , 2009, BMJ : British Medical Journal.

[13]  S. Toksvig-Larsen,et al.  Once-weekly oral medication with alendronate does not prevent migration of knee prostheses , 2009, Acta orthopaedica.

[14]  J. Lewsey,et al.  Revision Rates after Primary Hip and Knee Replacement in England between 2003 and 2006 , 2008, PLoS medicine.

[15]  A. Westfall,et al.  Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday , 2008, Osteoporosis International.

[16]  A. Goodship,et al.  Prevention of strain‐related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate , 2008, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[17]  Haitao Chu,et al.  Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution , 2007, Statistics in medicine.

[18]  J. Clohisy,et al.  Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies , 2007, Arthritis research & therapy.

[19]  P. Aspenberg,et al.  Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: A randomized, double-blind radiostereometric study of 50 patients , 2007, Acta orthopaedica.

[20]  D. Felsenberg.  Osteonecrosis of the jaw—a potential adverse effect of bisphosphonate treatment , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[21]  N. Watts,et al.  Bisphosphonates and osteonecrosis of the jaw. , 2006, Annals of internal medicine.

[22]  E. Brankin,et al.  The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases , 2006, Current medical research and opinion.

[23]  P. Aspenberg,et al.  Postoperative clodronate decreases prosthetic migration: 4–year follow-up of a randomized radiostereometric study of 50 total knee patients , 2006, Acta orthopaedica.

[24]  Patrick Royston,et al.  Multiple Imputation of Missing Values: Update of Ice , 2005 .

[25]  Ping Li,et al.  Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding , 2005, BMJ : British Medical Journal.

[26]  J. Ioannidis,et al.  Comparison of evidence of treatment effects in randomized and nonrandomized studies. , 2001, JAMA.

[27]  T. Walley,et al.  The UK General Practice Research Database , 1997, The Lancet.

[28]  C. Howie,et al.  Localised endosteal bone lysis in relation to the femoral components of cemented total hip arthroplasties. , 1990, The Journal of bone and joint surgery. British volume.

[29]  William H. Harris,et al.  Total Hip and Total Knee Replacement , 1990 .

[30]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[31]  J. Reginster.  Antifracture Efficacy of Currently Available Therapies for Postmenopausal Osteoporosis , 2012, Drugs.

[32]  Kevin Ong,et al.  The epidemiology of revision total hip arthroplasty in the United States. , 2009, The Journal of bone and joint surgery. American volume.